New dosing strategy aims to tame stem cell transplant complications

NCT ID NCT06265584

Recruiting now Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a two-step dosing schedule of anti-thymocyte globulin (ATG) combined with standard drugs (tacrolimus and mini methotrexate) to prevent severe graft-versus-host disease (GVHD) in 56 adults with blood cancers like acute leukemia. Participants receive ATG on days -7 to -1 before transplant, along with chemotherapy. The goal is to improve GVHD/relapse-free survival one year after transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anti-thymocyte globulin (ATG), tacrolimus, and mini methotrexate
What this could lead to: If successful, this approach could reduce severe graft-versus-host disease and improve survival without relapse after stem cell transplant.
What could go wrong: This is a small, early-phase trial (56 participants) testing a new dosing schedule. It may not prove effective or could have unexpected side effects like infections or organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia acute myeloid leukemia leukemia myelodysplastic syndrome Myelodysplastic Syndromes myelofibrosis Myeloproliferative Disorders myeloproliferative neoplasm acute graft versus host disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LEUKEMIA MYELODYSPLASTIC SYNDROME MYELOPROLIFERATIVE DISORDERS

Contacts and locations

Locations

University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.